Form 4: CSBR awards 13,790 options to director at $6.8

Rhea-AI Filing Summary

Champions Oncology (CSBR) reported a Form 4 showing a director was granted an option to purchase 13,790 shares of common stock on November 5, 2025 at an exercise price of $6.8 per share. The option has a ten-year term expiring on November 5, 2035.

The award vests over twelve months in four tranches on November 5, 2025, February 5, 2026, May 5, 2026, and August 5, 2026. Following the grant, the reporting person holds 13,790 derivative securities directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Breitfeld Philip P.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Option to purchase Common Stock	13,790	$6.80	$94K

Holdings After Transaction: Option to purchase Common Stock — 13,790 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Breitfeld Philip P.

(Last) (First) (Middle)

ONE UNIVERSITY PLAZA

SUITE 307

(Street)

HACKENSACK NJ 07601

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CHAMPIONS ONCOLOGY, INC. [ CSBR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to purchase Common Stock	$6.8	11/05/2025		A		13,790		(1)	11/05/2035	Common Stock	13,790	$6.8	13,790	D

Explanation of Responses:

1. The options vest over a twelve month period and are exercisable over a ten year period, with vesting to occur on November 5, 2025, February 5, 2026, May 5, 2026 and August 5, 2026, respectively.

Remarks:

	/s/ Philip P. Breitfeld	11/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Champions Oncology (CSBR) disclose in this Form 4?

A director received an option to purchase 13,790 CSBR common shares at an exercise price of $6.8 on November 5, 2025.

What is the exercise price and term of the CSBR option grant?

The exercise price is $6.8 per share, and the option expires on November 5, 2035.

How does the CSBR option vest?

It vests over twelve months in four tranches on Nov 5, 2025, Feb 5, 2026, May 5, 2026, and Aug 5, 2026.

How many derivative securities does the reporting person hold after this grant?

The reporting person beneficially owns 13,790 derivative securities directly after the reported transaction.

What role does the reporting person have at CSBR?

The reporting person is a Director of Champions Oncology.